




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 249/04, A61K 31/41	A1	(11) International Publication Number: WO 98/56773 (43) International Publication Date: 17 December 1998 (17.12.98)
(21) International Application Number: PCT/EP98/03428 (22) International Filing Date: 8 June 1998 (08.06.98) (30) Priority Data: 1404/97 10 June 1997 (10.06.97) CH (71) Applicant (for all designated States except AT US): NOVARTIS AG [CH/CH]; Schwarzwaldallee 215, CH-4058 Basel (CH). (71) Applicant (for AT only): NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H. [AT/AT]; Brunner Strasse 59, A-1235 Vienna (AT). (72) Inventors; and (75) Inventors/Applicants (for US only): PORTMANN, Robert [CH/CH]; Unterer Rütschetenweg 38, CH-4133 Pratteln (CH). HOFMEIER, Urs, Christoph [CH/CH]; Hauptstrasse 30, CH-4421 Pantaleon (CH). BURKHARD, Andreas [CH/CH]; Blotzheimerstrasse 29, CH-4055 Basel (CH). SCHERRER, Walter [CH/CH]; Habsburgerstrasse 62, CH-4310 Rheinfelden (CH). SZELAGIEWICZ, Martin [CH/CH]; Christoph-Merian-Strasse 1, CH-4142 Münchenstein (CH).		(74) Agent: BECKER, Konrad; Novartis AG, Patent- und Markenabteilung, Lichtstrasse 35, CH-4002 Basel (CH). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: CRYSTAL MODIFICATION OF 1-(2,6-DIFLUOROBENZYL)-1H-1,2,3-TRIAZOLE-4-CARBOXAMIDE AND ITS USE AS ANTIEPILEPTIC  (I) (57) Abstract The invention relates to the novel modifications B and C of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide of formula (I), its use for the treatment of epilepsy and pharmaceutical preparations comprising these crystal modifications.		

FOR THE PURPOSES OF INFORMATION ONLY


Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

CRYSTAL MODIFICATION OF 1-(2,6-DIFLUOROBENZYL)-1H-1,2,3-TRIAZOLE-4-CARBOXAMIDE AND ITS USE AS ANTIEPILEPTIC

Background of the invention

The compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide of the formula



is described in the European Patent Application with the Publication No. 0 199 262 A2 (EP 199262), for example in Example 4. Valuable pharmacological properties are attributed to this compound; thus, it can be used, for example, as an antiepileptic. The compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide is obtained according to EP 199262, starting from 2,6-difluorobenzyl azide via the formation of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxylic acid, the procedure being analogous to Example 2.

EP 199262 provides no information at all about possible crystal modifications obtained. If the method according to Example 4 is used in conjunction with Example 2, the crude 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide product obtained is finally crystallized from ethanol. However, EP 199262 gives no indication that such recrystallization is specifically to be applied, or on particular conditions that might be adopted. It has now surprisingly been found that the different crystal modifications (polymorphism) characterized below can be prepared by choice of specially selected process conditions, for example through the choice of an appropriate solvent for the recrystallization or the duration of the recrystallization.

Description of the invention

1-(2,6-Difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide can be obtained in the novel crystal modifications A, A', B and C. These crystal modifications differ with respect to their thermodynamic stability, in their physical parameters, such as the absorption pattern of IR and Raman spectra, in X-ray structure investigations and in their preparation processes.

The invention relates to the novel crystal modifications B and C, their preparation and use in pharmaceutical preparations comprising this crystal modification.

The modification A', compared with A, has defects in the crystal lattice. These are detectable, for example, by X-ray analysis, e.g. by smaller line spacings with otherwise predominantly identical lines or bands.

The crystal modification A of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide melts at 242°C (239-245°C).

In the FT infrared (FT-IR) spectrum (KBr pellet - transmission method), modification A or A' differs from modifications B and C predominantly in the shape and in the relative intensity of many bands. Particularly characteristic are the bands at 3412 cm^{-1} and 3092 cm^{-1} [cf. Figure 1], which are not present in the FT-IR spectra of the modifications B and C. In the range $4000\text{-}600\text{ cm}^{-1}$, inter alia the following bands are obtained for modification A: 3412, 3189, 3092, 1634, 1560, 1473, 1397, 1325, 1300, 1284, 1235, 1125, 1053, 1036, 1014, 885, 840, 799, 781, 723, 688 and 640 cm^{-1} . For example, the apparatus IFS 88 (Bruker) can be used for recording of each of the FT-IR spectra.

In the FT Raman spectrum (powder - reflection method 180°), the modification A or A' differs from modifications B and C predominantly in the shape and in the relative intensity of many bands. Particularly characteristic are the band at 1080 cm^{-1} [cf. Figure 2], which is not present in the Raman spectra of the modifications B and C. In the range $3400\text{-}300\text{ cm}^{-1}$,

inter alia the following bands are obtained for the modification A: 3093, 2972, 1628, 1614, 1558, 1465, 1446, 1393, 1279, 1245, 1147, 1080, 1061, 1036, 1014, 840, 724, 691, 667, 550, 499, 437 and 368 cm^{-1} . For example, the apparatus RFS 100 (Bruker) can be used for recording of each of the FT Raman spectra.

The modification A has an X-ray powder pattern with characteristic lines with interplanar spacings (d values) of 10.5 Å, 5.14 Å, 4.84 Å, 4.55 Å, 4.34 Å, 4.07 Å, 3.51 Å, 3.48 Å, 3.25 Å, 3.19 Å, 3.15 Å, 3.07 Å, 2.81 Å [cf. Table 1]. The measurement can be carried out, for example, in transmission geometry on an FR 552 Guinier camera from Enraf-Nonius, Delft (The Netherlands), using copper $K\alpha_1$ radiation (wavelength $\lambda = 1.54060\text{ Å}$). The patterns recorded on X-ray film were measured using an LS-18 line scanner from Johannsson, Täby (Sweden) and evaluated using the Scanpi software (P.E.Werner, University of Stockholm).

Characteristic for the modification A is the thermogram in differential scanning calorimetry. It has an endothermic peak in the range from 230°C to 260°C. The peak temperature is 239-245°C, and the endothermic signal is $209\text{ J/g} \pm 10\text{ J/g}$. The measurement was carried out on a Perkin Elmer DSC 7 in a closed pan with a heating rate of 20 K/minute. The typical sample quantity is about 4 mg. As a typical distinguishing feature compared with the modifications B and C, the thermogram of the modification A has no further thermal signal.

Crystals of the modification A' have the same crystal structure as modification A. They differ from the modification A in the X-ray powder pattern in that they have slightly smaller line spacings between specific pairs of lines. These are the pairs of lines with the following interplanar spacings: 3.68 Å and 3.64 Å, 3.51 Å and 3.48 Å, 3.19 Å and 3.15 Å.

In the FT-IR spectrum (KBr pellet - transmission method), the novel modification B differs from the modification A or A' and C predominantly in the shape and in the relative intensity of many bands. Particularly characteristic is a band at 1678 cm^{-1} [cf. Figure 1], which is not to be observed in the corresponding spectra of the modifications A and C. In the range

4000-600 cm^{-1} , inter alia the following bands are obtained for the modification B: 3404, 3199, 3125, 1678, 1635, 1560, 1475, 1393, 1357, 1322, 1286, 1237, 1051, 1036, 1028, 889, 837, 800, 719, 667 and 645 cm^{-1} . For example, the apparatus IFS 85 (Bruker) can be used for recording of each of the FT-IR spectra.

In the FT Raman spectrum (powder - reflection method 180°), the novel modification B differs from the modifications A or A' and C predominantly in the shape and in the relative intensity of many bands. Particularly characteristic are the bands at 3166 cm^{-1} and 1086 cm^{-1} [cf. Figure 2], which are not present in the Raman spectra of the modifications A and C. In the range 3400-300 cm^{-1} , inter alia the following bands are obtained for the modification B: 3166, 3089, 2970, 1678, 1628, 1614, 1559, 1464, 1441, 1391, 1275, 1244, 1147, 1086, 1062, 1036, 1014, 839, 773, 724, 690, 668, 595, 549, 500, 493, 430 and 365 cm^{-1} . For example, the apparatus RFS 100 (Bruker) can be used for recording of each of the FT Raman spectra.

The novel modification B has an X-ray powder pattern with characteristic lines with interplanar spacings (d values) of 11.0 Å, 8.3 Å, 5.18 Å, 4.88 Å, 4.80 Å, 4.42 Å, 4.33 Å, 4.19 Å, 4.12 Å, 3.81 Å, 3.50 Å, 3.41 Å, 3.36 Å, 3.32 Å, 3.28 Å, 3.24 Å, 3.05 Å, 2.83 Å [cf. Table 1].

In the thermogram in differential scanning calorimetry, the novel modification B has, in addition to an endothermic signal in the range from 230°C to 260°C (peak temperature 239°C - 245°C), a weak thermal signal at 205°C (180° - 220°C) as a typical distinguishing feature compared with the modifications A or A' and C.

In the FT-IR spectrum (KBr pellet - transmission method), the novel modification C differs from the modifications A or A' and B predominantly in the shape and in the relative intensity of many bands. Particularly characteristic is a band at 3137 cm^{-1} [cf. Figure 1], which is not to be observed in the corresponding spectra of the modifications A and B.

In the range 4000-600 cm^{-1} , inter alia the following bands are obtained for the novel modification C: 3396, 3287, 3137, 1657, 1631, 1602, 1559, 1475, 1392, 1323, 1287, 1237, 1122, 1104, 1047, 1035, 1012, 876, 839, 797, 773, 729 and 653 cm^{-1} . For example, the apparatus IFS 85 (Bruker) can be used for recording of each of the FT-IR spectra.

In the FT Raman spectrum (powder - reflection method 180°), the modification C differs from the modifications A or A' and B predominantly in the shape and in the relative intensity of many bands. Particularly characteristic are the bands at 3137 cm^{-1} and 1602 cm^{-1} [cf. Figure 2], which are not present in the Raman spectra of the modifications A and B. In the range 3400-300 cm^{-1} , inter alia the following bands are obtained for the modification C: 3137, 3080, 3012, 2971, 1673, 1629, 1602, 1561, 1436, 1271, 1248, 1105, 1065, 1035, 1013, 839, 800, 767, 726, 690, 672, 593, 549, 500, 492, 435 and 370 cm^{-1} . For example, the apparatus RFS 100 (Bruker) can be used for recording of each of the FT Raman spectra.

The novel modification C has an X-ray powder pattern with characteristic lines with interplanar spacings (d values) of 9.0 Å, 4.73 Å, 4.65 Å, 3.75 Å, 3.54 Å, 3.42 Å, 3.25 Å [cf. Table 1]. In the thermogram in differential scanning calorimetry, the modification C has, in addition to an endothermic signal in the range of 230°C to 260°C (peak temperature 239-245°C), a very broad, weak, exothermic signal in the region of 180°C compared with the modifications A or A' and B.

Table 1: Characterization of the modifications A, B and C (X-ray powder patterns):

Modification A:		Modification B:		Modification C:	
d [Å]	Intensity	d [Å]	Intensity	d [Å]	Intensity
10.9	weak	11.0	medium	9.0	medium
10.5	medium	8.3	medium	7.0	weak
6.6	weak	8.1	very weak	5.49	weak
5.63	weak	5.68	very weak	5.11	very weak
5.25	weak	5.18	very strong	4.80	weak

5.14	medium	5.11	weak	4.73	strong
4.94	weak	4.88	medium	4.65	very strong
4.84	very strong	4.80	strong	4.47	very weak
4.55	strong	4.71	very weak	4.19	very weak
4.42	very weak	4.61	weak	4.11	very weak
4.34	medium	4.45	weak	3.98	very weak
4.23	very weak	4.42	strong	3.83	very weak
4.16	weak	4.33	very strong	3.75	strong
4.07	medium	4.19	medium	3.73	weak
4.01	weak	4.12	strong	3.54	medium
3.68	very weak	4.09	weak	3.50	weak
3.64	very weak	3.99	very weak	3.42	strong
3.60	weak	3.95	very weak	3.25	medium
3.56	weak	3.84	weak	2.88	very weak
3.51	medium	3.81	medium	2.80	very weak
3.48	medium	3.65	weak	2.74	very weak
3.38	very weak	3.61	very weak	2.67	very weak
3.25	strong	3.58	very weak	2.64	weak
3.19	medium	3.54	weak		
3.15	medium	3.50	medium		
3.11	weak	3.47	very weak		
3.07	medium	3.41	medium		
2.93	very weak	3.36	very strong		
2.87	very weak	3.32	strong		
2.81	medium	3.28	medium		
2.76	weak	3.24	medium		
2.73	very weak	3.10	weak		
2.68	weak	3.07	weak		
2.62	very weak	3.05	medium		
2.53	weak	2.93	weak		
2.43	weak	2.88	weak		
2.40	very weak	2.87	very weak		
		2.83	medium		
		2.66	weak		
		2.63	very weak		
		2.55	weak		
		2.50	weak		
		2.46	weak		
		2.44	weak		
		2.37	weak		
		2.35	weak		

Single crystal X-ray analysis:

Crystal quality and unit cell of modifications A, B, and C were verified by Weissenberg and precession photographs. The intensities were measured on a four-axis Nonius CAD-4 diffractometer. The structures were solved with the SHELXS-97 and refined with the SHELXL-97 software.

Modification A

Space group: Pna2₁ - orthorhombic

Cell dimensions:

a = 24.756 (5) Å	b = 23.069 (4) Å	c = 5.386 (1) Å
V = 3075.9 Å ³	Z = 12	D _x = 1.543 gcm ⁻³
v per formula:	V _z = 256.3 Å ³	

9011 unique reflections; 2479 thereof significant with $I > 2\sigma(I)$. 557 parameters refined.

Position of all H atoms found by difference Fourier maps and refined isotropically.

Reliability index R₁: 3.65% (wR₂ for all 9011 reflections: 11.34%).

Modification B

Space group: P $\bar{1}$ -triclinic

Cell dimensions:

a = 5.326(1) Å	b = 11.976(2) Å	c = 17.355(3) Å
$\alpha = 107.22(3)^\circ$	$\beta = 92.17(3)^\circ$	$\gamma = 102.11(3)^\circ$
V = 1027.9 Å ³	Z = 4	D _x = 1.539 gcm ⁻³
v per formula	V _z = 257.0 Å ³	

4934 unique reflections; 834 thereof significant with $I > 2\sigma(I)$. 232 parameters refined.

- 8 -

Position of all H atoms found by difference Fourier maps and refined isotropically.
Reliability index R_1 : 4.20% (wR_2 for all 4934 reflections: 7.93%).

Modification C

Space group: $P2_1/C$ - monoclinic

Cell dimensions:

$a = 10.982(2) \text{ \AA}$	$b = 5.350(1) \text{ \AA}$	$c = 17.945(3) \text{ \AA}$
	$\beta = 91.59(1)^\circ$	
$V = 1053.9 \text{ \AA}^3$	$Z = 4$	$D_x = 1.501 \text{ gcm}^{-3}$
V per formula:	$V_z = 263.5 \text{ \AA}^3$	

3073 unique reflections; 1071 thereof significant with $I > 2\sigma(I)$. 187 parameters refined.

Position of all H atoms found by difference Fourier maps and refined isotropically.

Reliability index R_1 : 5.02% (wR_2 for all 3073 reflections: 14.55%).

Modifications A, A', B and C have valuable pharmacological properties; in particular, they can be used for the treatment of epilepsy.

The modifications B and C have significant advantages compared with the modification A or A'.

Thus, it was found, for example, that modification B has a substantially faster dissolution rate in water and gastric fluid than modification A or A'. Consequently, when modification B is used therapeutically, a rapid onset of action is achieved, which is particularly advantageous, for example in an acute epilepsy attack.

The invention relates to the modification B of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide, having the following absorption in the infrared spectrum (KBr pellet - transmission method): band at 1678 cm^{-1} .

The invention relates to the modification B of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide, having characteristic lines with interplanar spacings (d values) of 11.0 Å, 8.3 Å, 5.18 Å, 4.88 Å, 4.80 Å, 4.42 Å, 4.33 Å, 4.19 Å, 4.12 Å, 3.81 Å, 3.50 Å, 3.41 Å, 3.36 Å, 3.32 Å, 3.28 Å, 3.24 Å, 3.05 Å and 2.83 Å, determined by means of an X-ray powder pattern.

The invention relates to the modification B of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide, having the characteristic lines with interplanar spacings (d values) as shown in Table 1.

The invention relates to the modification B of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide, having in the thermogram in differential scanning calorimetry a weak thermal signal at 205°C (180-220°C) in addition to an endothermic signal in the range from 230°C to 260°C (peak temperature 239-245°C).

The invention furthermore relates to the crystal modification C of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide, having the following absorption in the infrared spectrum (KBr pellet - transmission method): band at 3137 cm⁻¹.

The invention relates to the modification C of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide, having characteristic lines with interplanar spacings (d values) of 9.0 Å, 4.73 Å, 4.65 Å, 3.75 Å, 3.54 Å, 3.42 Å, 3.25 Å, determined by means of an X-ray powder pattern.

The invention relates to modification C of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide, having the characteristic lines with interplanar spacings (d values) as shown in Table 1.

The invention relates to the modification C of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-

carboxamide, having in the thermogram in differential scanning calorimetry a very broad weak exothermic signal in the region of 180°C, in addition to an endothermic signal in the range from 230°C-260°C (peak temperature 239-245°C).

The invention relates to the essentially pure forms of the modifications B and C of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide. The term "essentially pure form" means purity of >95%, in particular >98%, primarily >99%, based on the modifications B and C.

The invention relates to pharmaceutical preparations comprising the modifications B and C of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide. The invention relates in particular to corresponding pharmaceutical preparations for the treatment of epilepsy and subindications thereof. The invention relates to the use of the modifications B and C of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide for the preparation of pharmaceutical preparations, in particular for the treatment of epilepsy and subindications thereof.

The novel modifications B and C of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide can be used, for example, in the form of pharmaceutical preparations which comprise a therapeutically effective amount of the active ingredient, if desired together with inorganic or organic, solid or liquid, pharmaceutically usable carriers, which are suitable for enteral, for example oral, or parenteral administration. Furthermore, the novel modifications B and C of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide can be used in the form of preparations which can be administered parenterally or of infusion solutions. The pharmaceutical preparations may be sterilized and/or may comprise excipients, for example preservatives, stabilizers, wetting agents and/or emulsifiers, solubilizers, salts for regulating the osmotic pressure and/or buffers. The present pharmaceutical preparations comprise from about 0.1% to 100%, in particular from about 1% to about 50%, of lyophilisates to about 100% of the active ingredient.

The invention also relates to the use of the modifications B and C of 1-(2,6-difluorobenzyl)-

1H-1,2,3-triazole-4-carboxamide as a drug, preferably in the form of pharmaceutical preparations. The dosage may depend on various factors, such as method of administration, species, age and/or individual condition. The doses to be administered daily are between about 0.25 and about 10 mg/kg in the case of oral administration, and preferably between about 20 mg and about 500 mg for warm-blooded species having a body weight of about 70 kg.

The preparation of the modifications B and C is carried out, for example, as described in the embodiments below.

Example 1: Modification B

1-(2,6-Difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide (18.29 kg) is dissolved in formic acid (89.3 kg) at 58-63°C while stirring. The solution is discharged in the course of about 30 minutes onto stirred methanol (105.5 l) at 20°C to 0°C, after which washing with formic acid (6.1 kg) is carried out. A suspension forms. The product is isolated immediately by filtration and washed with cold methanol (150 l, about 4°C). By drying in vacuo at about 60°C, the product is obtained as modification B in a yield of about 94%.

Example 2: Modification C

1-(2,6-Difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide (15.0 g) is dissolved in acetic acid (120 ml) at about 90°C while stirring. The solution is cooled to 20°C in the course of about 8 minutes, a suspension forming. The product is immediately isolated by filtration, washed with toluene (120 ml) and dried in vacuo at about 60°C. 10.1 g of the product are obtained as modification C. Yield 67.3%.

Formulation Example 1:

Film-coated tablets each containing, for example, 100, 200 or 400 mg of the modification B

- 12 -

or C of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide with the following composition per dosage unit:

Core material	mg	mg	mg
Active ingredient	100.00	200.00	400.00
Anhydrous, colloidal silica	0.88	1.75	3.5
Microcrystalline cellulose	36.62	73.25	146.50
Hydroxypropylmethyl-cellulose	5.00	10.00	20.00
Lactose	20.00	40.00	80.00
Magnesium stearate	2.00	4.00	8.00
Maize starch	10.00	20.00	40.00
Sodium carboxymethyl-cellulose	5.00	10.00	20.00
Sodium laurylsulfate	0.50	1.00	2.00
Film coat	mg	mg	mg
Hydroxypropylmethyl-cellulose	3.22	6.43	12.87
Red iron oxide	0.04	0.09	0.18
Polyethylene glycol 8000, flakes	0.58	1.16	2.32
Talc	2.33	4.66	9.31
Titanium dioxide	0.83	1.66	3.32

The active ingredient is granulated with demineralized water. Milled lactose, maize starch, Avicel PH 102, cellulose-HP-M-603 and sodium laurylsulfate are added to the above

mixture and granulated with demineralized water.

The moist material is dried and milled. After the addition of the remaining ingredients, the homogeneous mixture is compressed to give tablet cores having the stated active ingredient content.

The tablet cores are coated with the film coat which is formed from the appropriate ingredients, the latter being dissolved or being suspended in water or in small amounts of ethanol with 5% of isopropanol.

Description of the Figures


Figure 1 shows the FT-IR spectra of the KBr pellets of crystal modifications A, B and C.

Figure 2 shows the FT-Raman spectra of the powder of modifications A, B and C.

In both Figures, the modification A is denoted by the symbol *, the modification B by the symbol ** and the modification C by the symbol ***.

WHAT IS CLAIMED IS:

1. A modification B of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide of the formula




having characteristic lines with interplanar spacings (d values) of 11.0 Å, 8.3 Å, 5.18 Å, 4.88 Å, 4.80 Å, 4.42 Å, 4.33 Å, 4.19 Å, 4.12 Å, 3.81 Å, 3.50 Å, 3.41 Å, 3.36 Å, 3.32 Å, 3.28 Å, 3.24 Å, 3.05 Å and 2.83 Å, determined by means of an X-ray powder pattern.

2. A modification according to claim 1, which has an X-ray powder pattern having the following characteristic lines with interplanar spacings (d values) of 11.0 Å (medium), 8.3 Å (medium), 8.1 Å (very weak), 5.68 Å (very weak), 5.18 Å (very strong), 5.11 Å (weak), 4.88 Å (medium), 4.80 Å (strong), 4.71 Å (very weak), 4.61 Å (weak), 4.45 Å (weak), 4.42 Å (strong), 4.33 Å (very strong), 4.19 Å (medium), 4.12 Å (strong), 4.09 Å (weak), 3.99 Å (very weak), 3.95 Å (very weak), 3.84 Å (weak), 3.81 Å (medium), 3.65 Å (weak), 3.61 Å (very weak), 3.58 Å (very weak), 3.54 Å (weak), 3.50 Å (medium), 3.47 Å (very weak), 3.41 Å (medium), 3.36 Å (very strong), 3.32 Å (strong), 3.28 Å (medium), 3.24 Å (medium), 3.10 Å (weak), 3.07 Å (weak), 3.05 Å (medium), 2.93 Å (weak), 2.88 Å (weak), 2.87 Å (very weak), 2.83 Å (medium), 2.66 Å (weak), 2.63 Å (very weak), 2.55 Å (weak), 2.50 Å (weak), 2.46 Å (weak), 2.44 Å (weak), 2.37 Å (weak), 2.35 Å (weak).

- 15 -

3. A modification according to claim 1 or 2, having the following absorption in the FT-IR spectrum (KBr pellet - transmission method): 1678 cm^{-1} .
4. A modification according to claim 3, having the following absorptions in the FT-IR spectrum (KBr pellet - transmission method): $3404, 3199, 3125, 1678, 1635, 1560, 1475, 1393, 1357, 1322, 1286, 1237, 1051, 1036, 1028, 889, 837, 800, 719, 667$ and 645 cm^{-1} .
5. A modification according to any one of claims 1-4, having the following absorptions in the FT-Raman spectrum (powder - reflection method 180°): $3166, 3089, 2970, 1678, 1628, 1614, 1559, 1464, 1441, 1391, 1275, 1244, 1147, 1086, 1062, 1036, 1014, 839, 773, 724, 690, 668, 595, 549, 500, 493, 430$ and 365 cm^{-1} .
6. A modification B according to any one of claims 1-5, having in the thermogram in differential scanning calorimetry a weak thermal signal at 205°C ($180\text{-}220^\circ\text{C}$) in addition to an endothermic signal in the range from 230°C to 260°C (peak temperature $239\text{-}245^\circ\text{C}$).
7. A modification C of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide of the formula



having characteristic lines with interplanar spacings (d values) of $9.0\text{ \AA}$, $4.73\text{ \AA}$, $4.65\text{ \AA}$, $3.75\text{ \AA}$, $3.54\text{ \AA}$, $3.42\text{ \AA}$, $3.25\text{ \AA}$, determined by means of an X-ray powder pattern.

8. A modification according to claim 7, having an X-ray powder pattern with the

following characteristic lines with interplanar spacings (d values) of 9.0 Å (medium), 7.0 Å (weak), 5.49 Å (weak), 5.11 Å (very weak), 4.80 Å (weak), 4.73 Å (strong), 4.65 Å (very strong), 4.47 Å (very weak), 4.19 Å (very weak), 4.11 Å (very weak), 3.98 Å (very weak), 3.83 Å (very weak), 3.75 Å (strong), 3.73 Å (weak), 3.54 Å (medium), 3.50 Å (weak), 3.42 Å (strong), 3.25 Å (medium), 2.88 Å (very weak), 2.80 Å (very weak), 2.74 Å (very weak), 2.67 Å (very weak), 2.64 Å (weak).

9. A modification according to claim 7 or 8, having the following absorption in the infrared spectrum (KBr pellet - transmission method): 3137 cm⁻¹.

10. A modification according to claim 9, having the following absorptions in the infrared spectrum (KBr pellet - transmission method): 3396, 3287, 3137, 1657, 1631, 1602, 1559, 1475, 1392, 1323, 1287, 1237, 1122, 1104, 1047, 1035, 1012, 876, 839, 797, 773, 729 and 653 cm⁻¹.

11. A modification according to any one of claims 7-10, having the following absorptions in the FT-Raman spectrum (powder - reflection method 180°): 3137, 3080, 3012, 2971, 1673, 1629, 1602, 1561, 1436, 1271, 1248, 1105, 1065, 1035, 1013, 839, 800, 767, 726, 690, 672, 593, 549, 500, 492, 435 and 370 cm⁻¹.

12. A modification C according to any one of claims 7-11, having in the thermogram in differential scanning calorimetry a very broad, weak, exothermic signal in the region of 180°C, in addition to an endothermic signal in the range from 230°C to 260°C (peak temperature 239-245°C).

13. A modification B or C according to any one of claims 1-12 in essentially pure form.

14. A pharmaceutical preparation comprising the modification B or C of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide according to any one of claims 1-13

and pharmaceutically usable excipients and additives.

15. The use of the modification B or C of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide according to any one of claims 1-13 as a pharmaceutical preparation.

16. The use of the modification B or C of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide according to any one of claims 1-13 for the preparation of a pharmaceutical preparation for the treatment of epilepsy and subindications thereof.

1/2

FIGURE 1





FIGURE 2



INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 98/03428

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D249/04 A61K31/41

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 199 262 A (CIBA-GEIGY AG) 29 October 1986 cited in the application see the whole document, particularly example 4	1-16
A	MÜNDEL K: "Der Einfluss der Formgebung auf die Wirkung eines Arzneimittels" FORTSCHRITTE DER ARZNEIMITTELFORSCHUNG - PROGRESS IN DRUG RESEARCH - PROGRÈS DES RECHERCHES PHARMACEUTIQUES, vol. 10, 1966, pages 227-30, XP002078506 Basel, CH	1-16



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

23 September 1998

Date of mailing of the international search report

07/10/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Allard, M

INTERNATIONAL SEARCH REPORT

Internat. Application No
PCT/EP 98/03428

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	MÜNZEL K: "Galenische Formgebung und Arzneimittelwirkung / Neue Erkenntnisse und Feststellungen" PROGRESS IN DRUG RESEARCH - FORTSCHRITTE DER ARZNEIMITTELFORSCHUNG - PROGRÈS DES RECHERCHES PHARMACEUTIQUES, vol. 14, 1970, pages 309-21, XP002078507 Basel, CH -----	1-16

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 98/ 03428

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 15
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim 15
is directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern: al Application No

PCT/EP 98/03428

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 199262 A	29-10-1986	AU 599024 B	12-07-1990
		AU 5631986 A	23-10-1986
		CA 1272201 A	31-07-1990
		CY 1751 A	03-06-1994
		DD 245874 A	20-05-1987
		DK 175686 A	19-10-1986
		FI 861573 A,B,	19-10-1986
		HK 1494 A	14-01-1994
		IE 58472 B	22-09-1993
		JP 1848050 C	07-06-1994
		JP 61243068 A	29-10-1986
		MX 9203628 A	01-09-1992
		PT 82400 B	17-08-1988
		SG 142293 G	31-03-1994
		US 4789680 A	06-12-1988